Recombinant Plasma Protein Therapeutics
The global Recombinant Plasma Protein Therapeutics market was valued at 7571.7 Million USD in 2021 and will grow with a CAGR of 4.97% from 2021 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant therapies, rise in awareness about rare disease management and increased focus on investments in rare diseases.Rising demand from Asia-Pacific region is a major driver for the growth of the market.
By Market Verdors
CSL Limited
Takeda
Octapharma
Novo Nordisk A/S
Pfizer
Bioverativ Therapeutics
Aptevo Therapeutics
Pharming Group
By Types
Recombinant Coagulation Factors
Human C1 Esterase Inhibitor
By Applications
Hemophilia A
Hemophilia B
Von Willebrand Disease
Key Indicators Analysed
Market Players & Competitor AnalysisThe report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market AnalysisThe report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market TrendsMarket key trends which include Increased Competition and Continuous Innovations.
Opportunities and DriversIdentifying the Growing Demands and New Technology
Porters Five Force AnalysisThe report provides with the state of competition in industry depending on five basic forcesthreat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements
Table of Content
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Recombinant Plasma Protein Therapeutics Revenue
1.4 Market Analysis by Type
1.4.1 Global Recombinant Plasma Protein Therapeutics Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Recombinant Coagulation Factors
1.4.3 Human C1 Esterase Inhibitor
1.5 Market by Application
1.5.1 Global Recombinant Plasma Protein Therapeutics Market Share by Application: 2022-2027
1.5.2 Hemophilia A
1.5.3 Hemophilia B
1.5.4 Von Willebrand Disease
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Recombinant Plasma Protein Therapeutics Market
1.8.1 Global Recombinant Plasma Protein Therapeutics Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Recombinant Plasma Protein Therapeutics Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Recombinant Plasma Protein Therapeutics Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Recombinant Plasma Protein Therapeutics Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Recombinant Plasma Protein Therapeutics Sales Volume Market Share by Region (2016-2021)
3.2 Global Recombinant Plasma Protein Therapeutics Sales Revenue Market Share by Region (2016-2021)
3.3 North America Recombinant Plasma Protein Therapeutics Sales Volume
3.3.1 North America Recombinant Plasma Protein Therapeutics Sales Volume Growth Rate (2016-2021)
3.3.2 North America Recombinant Plasma Protein Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Recombinant Plasma Protein Therapeutics Sales Volume
3.4.1 East Asia Recombinant Plasma Protein Therapeutics Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Recombinant Plasma Protein Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Recombinant Plasma Protein Therapeutics Sales Volume (2016-2021)
3.5.1 Europe Recombinant Plasma Protein Therapeutics Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Recombinant Plasma Protein Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Recombinant Plasma Protein Therapeutics Sales Volume (2016-2021)
3.6.1 South Asia Recombinant Plasma Protein Therapeutics Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Recombinant Plasma Protein Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Recombinant Plasma Protein Therapeutics Sales Volume (2016-2021)
3.7.1 Southeast Asia Recombinant Plasma Protein Therapeutics Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Recombinant Plasma Protein Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Recombinant Plasma Protein Therapeutics Sales Volume (2016-2021)
3.8.1 Middle East Recombinant Plasma Protein Therapeutics Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Recombinant Plasma Protein Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Recombinant Plasma Protein Therapeutics Sales Volume (2016-2021)
3.9.1 Africa Recombinant Plasma Protein Therapeutics Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Recombinant Plasma Protein Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Recombinant Plasma Protein Therapeutics Sales Volume (2016-2021)
3.10.1 Oceania Recombinant Plasma Protein Therapeutics Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Recombinant Plasma Protein Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Recombinant Plasma Protein Therapeutics Sales Volume (2016-2021)
3.11.1 South America Recombinant Plasma Protein Therapeutics Sales Volume Growth Rate (2016-2021)
3.11.2 South America Recombinant Plasma Protein Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Recombinant Plasma Protein Therapeutics Sales Volume (2016-2021)
3.12.1 Rest of the World Recombinant Plasma Protein Therapeutics Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Recombinant Plasma Protein Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Recombinant Plasma Protein Therapeutics Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Recombinant Plasma Protein Therapeutics Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Recombinant Plasma Protein Therapeutics Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Recombinant Plasma Protein Therapeutics Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Recombinant Plasma Protein Therapeutics Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Recombinant Plasma Protein Therapeutics Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Recombinant Plasma Protein Therapeutics Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Recombinant Plasma Protein Therapeutics Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Recombinant Plasma Protein Therapeutics Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Recombinant Plasma Protein Therapeutics Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Recombinant Plasma Protein Therapeutics Sales Volume Market Share by Type (2016-2021)
14.2 Global Recombinant Plasma Protein Therapeutics Sales Revenue Market Share by Type (2016-2021)
14.3 Global Recombinant Plasma Protein Therapeutics Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Recombinant Plasma Protein Therapeutics Consumption Volume by Application (2016-2021)
15.2 Global Recombinant Plasma Protein Therapeutics Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Recombinant Plasma Protein Therapeutics Business
16.1 CSL Limited
16.1.1 CSL Limited Company Profile
16.1.2 CSL Limited Recombinant Plasma Protein Therapeutics Product Specification
16.1.3 CSL Limited Recombinant Plasma Protein Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Takeda
16.2.1 Takeda Company Profile
16.2.2 Takeda Recombinant Plasma Protein Therapeutics Product Specification
16.2.3 Takeda Recombinant Plasma Protein Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Octapharma
16.3.1 Octapharma Company Profile
16.3.2 Octapharma Recombinant Plasma Protein Therapeutics Product Specification
16.3.3 Octapharma Recombinant Plasma Protein Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Novo Nordisk A/S
16.4.1 Novo Nordisk A/S Company Profile
16.4.2 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Product Specification
16.4.3 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Pfizer
16.5.1 Pfizer Company Profile
16.5.2 Pfizer Recombinant Plasma Protein Therapeutics Product Specification
16.5.3 Pfizer Recombinant Plasma Protein Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Bioverativ Therapeutics
16.6.1 Bioverativ Therapeutics Company Profile
16.6.2 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Product Specification
16.6.3 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Aptevo Therapeutics
16.7.1 Aptevo Therapeutics Company Profile
16.7.2 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Product Specification
16.7.3 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Pharming Group
16.8.1 Pharming Group Company Profile
16.8.2 Pharming Group Recombinant Plasma Protein Therapeutics Product Specification
16.8.3 Pharming Group Recombinant Plasma Protein Therapeutics Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Recombinant Plasma Protein Therapeutics Manufacturing Cost Analysis
17.1 Recombinant Plasma Protein Therapeutics Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Recombinant Plasma Protein Therapeutics
17.4 Recombinant Plasma Protein Therapeutics Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Recombinant Plasma Protein Therapeutics Distributors List
18.3 Recombinant Plasma Protein Therapeutics Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Recombinant Plasma Protein Therapeutics (2022-2027)
20.2 Global Forecasted Revenue of Recombinant Plasma Protein Therapeutics (2022-2027)
20.3 Global Forecasted Price of Recombinant Plasma Protein Therapeutics (2016-2027)
20.4 Global Forecasted Production of Recombinant Plasma Protein Therapeutics by Region (2022-2027)
20.4.1 North America Recombinant Plasma Protein Therapeutics Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Recombinant Plasma Protein Therapeutics Production, Revenue Forecast (2022-2027)
20.4.3 Europe Recombinant Plasma Protein Therapeutics Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Recombinant Plasma Protein Therapeutics Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Recombinant Plasma Protein Therapeutics Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Recombinant Plasma Protein Therapeutics Production, Revenue Forecast (2022-2027)
20.4.7 Africa Recombinant Plasma Protein Therapeutics Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Recombinant Plasma Protein Therapeutics Production, Revenue Forecast (2022-2027)
20.4.9 South America Recombinant Plasma Protein Therapeutics Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Recombinant Plasma Protein Therapeutics Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Recombinant Plasma Protein Therapeutics by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Recombinant Plasma Protein Therapeutics by Country
21.2 East Asia Market Forecasted Consumption of Recombinant Plasma Protein Therapeutics by Country
21.3 Europe Market Forecasted Consumption of Recombinant Plasma Protein Therapeutics by Countriy
21.4 South Asia Forecasted Consumption of Recombinant Plasma Protein Therapeutics by Country
21.5 Southeast Asia Forecasted Consumption of Recombinant Plasma Protein Therapeutics by Country
21.6 Middle East Forecasted Consumption of Recombinant Plasma Protein Therapeutics by Country
21.7 Africa Forecasted Consumption of Recombinant Plasma Protein Therapeutics by Country
21.8 Oceania Forecasted Consumption of Recombinant Plasma Protein Therapeutics by Country
21.9 South America Forecasted Consumption of Recombinant Plasma Protein Therapeutics by Country
21.10 Rest of the world Forecasted Consumption of Recombinant Plasma Protein Therapeutics by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices